Claims for Patent: 10,744,228

Summary for Patent: 10,744,228

Title:	Methacrylated devitalized cartilage and devitalized cartilage particles
Abstract:	An implantable composition can include methacrylated solubilized devitalized cartilage (MeSDVC) with or without devitalized cartilage (DVC) particles. These compositions can be hydrogel precursors. After implantation, the MeSDVC may be crosslinked so as to form a hydrogel. The crosslinked hydrogel can include the DVC particles. A hydrogel precursor matrix (e.g., not crosslinked) can include a crosslinkable substance that can be crosslinked into a hydrogel, where DVC particles are included in the precursor matrix. The hydrogel precursor matrix can be located in a tissue defect site, such as a hole or recess in a cartilage or bone, and then crosslinked into a hydrogel that has the DVC particles therein.
Inventor(s):	Michael Detamore, Emily Beck
Assignee:	University of Kansas
Application Number:	US15/254,709

Details for Patent 10,744,228

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bristol-myers Squibb Company	YERVOY	ipilimumab	Injection	125377	March 25, 2011		2036-09-01
Janssen Biotech, Inc.	STELARA	ustekinumab	Injection	761044	September 23, 2016		2036-09-01

International Patent Family for US Patent 10,744,228

Country	Patent Number	Estimated Expiration
United States of America	2017065742